Cancer Causes & Control

, Volume 9, Issue 1, pp 83–88 | Cite as

Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States)

  • Lynn Rosenberg
  • R. Sowmya Rao
  • Julie R. Palmer
  • Brian L. Strom
  • Ann Zauber
  • M. Ellen Warshauer
  • Paul D. Stolley
  • Samuel Shapiro
Article

Abstract

Experimental and epidemiologic evidence have suggested that phenacetin use increases the risk of transitional cell cancers of the urinary tract. The drug is no longer marketed but a commonly used metabolite, acetaminophen, has been linked recently to an increased risk of renal cancer. We assessed the relation of acetaminophen use to the risk of transitional cell cancer of the urinary tract and of renal cell cancer with data from a hospital-based study of cancers and medication use conducted from 1976-96 in the eastern United States. We compared 498 cases of transitional cell cancer and 383 cases of renal cell cancer with 8,149 noncancer controls and 6,499 cancer controls and controlled confounding factors with logistic regression. For transitional cell cancer, the relative risk (RR) estimate for regular acetaminophen use that had begun at least a year before admission was 1.1 (95 percent confidence interval [CI] = 0.6-1.9) based on noncancer controls, and 0.9 (CI = 0.5-1.6) based on cancer controls. RR estimates for use that lasted at least five years, and for nonregular use, were also close to 1.0. For renal cell cancer, the corresponding estimates were again close to 1.0. Our results suggest that acetaminophen, as used in present study population, does not influence the risk of transitional cell cancer of the urinary tract or of renal cell cancer.

Acetaminophen kidney neoplasms renal cell carcinoma United States 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    International Agency for Research on Cancer. Some Pharmaceutical Drugs. Lyon, France: IARC, 1980; IARC Monogr Eval Carcinog Risk Chem Humans, Vol. 24: 135–61.Google Scholar
  2. 2.
    International Agency for Research on Cancer. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Lyon, France: IARC, 1987; IARC Monogr Eval Carcinog Risk Chem HumansSuppl. 7: 310–2.Google Scholar
  3. 3.
    Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med1985; 313: 292–5.Google Scholar
  4. 4.
    Stolley PD. The risks of phenacetin use. N Engl J Med1991; 324: 191–3.Google Scholar
  5. 5.
    Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology1996; 7: 358–62.Google Scholar
  6. 6.
    Shapiro S. Case-control surveillance. In: Strom BL, ed. Pharmacoepidemiology, 2nd Edition. Chichester, UK: John Wiley and Sons, 1994: 301–22.Google Scholar
  7. 7.
    Schlesselman JS. Case-control Studies: Design, Conduct, Analysis. New York, NY (USA): Oxford University Press, 1982.Google Scholar
  8. 8.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: NSAIDs reduce the incidence of large bowel cancer. J Natl Cancer Inst1991; 83: 355–8.Google Scholar
  9. 9.
    Berkel HJ, Holcombe RF, Middlebrooks M, Kannan K. Nonsteroidal antiinflammatory drugs and colorectal cancer. Epidemiol Rev1996; 18: 205–17.Google Scholar
  10. 10.
    International Agency for Research on Cancer. Pharmaceutical Drugs. Lyon, France: IARC, 1990; IARC Monogr Eval Carcinog Risks Humans, Vol. 50: 307–32.Google Scholar
  11. 11.
    Toxicology and carcinogenesis studies of acetaminophen (CAS No. 103-90-2) in F344/N rats and B6C3F1 mice (feed studies). National Toxicology Program: Technical Report Series No. 394. US Department of Health and Human Services.Google Scholar
  12. 12.
    McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni JF Jr. Etiology of cancer of the renal pelvis. J Natl Cancer Inst1983; 71: 287–91.Google Scholar
  13. 13.
    McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer1993; 53: 245–9.Google Scholar
  14. 14.
    Ross RK, Paganini-Hill A, Landolf J, Gerkens V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res1989; 49: 1045–8.Google Scholar
  15. 15.
    Steineck G, Wiholm BE, DeVerdier MG. Acetaminophen, some other drugs, some diseases, and risk of transitional cell carcinoma. Acta Oncologica1995; 34: 741–8.Google Scholar
  16. 16.
    Linet MS, Chow WH, McLaughlin JK, et al.Analgesics and cancers of the renal pelvis and ureter. Int J Cancer1995; 62: 15–18.Google Scholar
  17. 17.
    McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF Jr. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst1984; 72: 275–84.Google Scholar
  18. 18.
    McLaughlin JK, Gao VT, Gao RN, et al.Risk factors for renal-cell cancer in Shanghai China. Int J Cancer1992; 52: 562–5.Google Scholar
  19. 19.
    Krieger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control1993; 4: 101–10.Google Scholar
  20. 20.
    McCredie M, Pommer W, McLaughlin JK, et al.International renal-cell cancer study. II. Analgesics. Int J Cancer1995; 60: 345–9.Google Scholar

Copyright information

© Chapman and Hall 1998

Authors and Affiliations

  • Lynn Rosenberg
    • 1
  • R. Sowmya Rao
    • 1
  • Julie R. Palmer
    • 1
  • Brian L. Strom
    • 2
  • Ann Zauber
    • 3
  • M. Ellen Warshauer
    • 4
  • Paul D. Stolley
    • 5
  • Samuel Shapiro
    • 1
  1. 1.School of Public HealthBoston University School of MedicineBrooklineUSA
  2. 2.Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, and Division of General Internal Medicine of the Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Department of Public HealthCornell Medical Center, New York HospitalNew YorkUSA
  5. 5.Department of Epidemiology and Preventive MedicineUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations